Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-30
Target enrollment:
Participant gender:
Summary
In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.